vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Legacy Housing Corp (LEGH). Click either name above to swap in a different company.
Legacy Housing Corp is the larger business by last-quarter revenue ($25.5M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). Legacy Housing Corp runs the higher net margin — 32.2% vs -0.8%, a 33.0% gap on every dollar of revenue. On growth, CytomX Therapeutics, Inc. posted the faster year-over-year revenue change (-25.7% vs -30.6%). Legacy Housing Corp produced more free cash flow last quarter ($15.7M vs $-15.8M). Over the past eight quarters, Legacy Housing Corp's revenue compounded faster (-9.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Legacy Housing Corp is a prominent U.S.-based manufacturer of affordable manufactured homes, tiny homes, and accessory dwelling units. It mainly caters to low- and middle-income consumers across North America, providing customizable residential solutions, supporting construction materials, and after-sales services for individual and community development clients.
CTMX vs LEGH — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $25.5M |
| Net Profit | $-154.0K | $8.2M |
| Gross Margin | — | 26.4% |
| Operating Margin | -6.9% | 40.4% |
| Net Margin | -0.8% | 32.2% |
| Revenue YoY | -25.7% | -30.6% |
| Net Profit YoY | 97.6% | -43.5% |
| EPS (diluted) | — | $0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $25.5M | ||
| Q3 25 | — | $28.8M | ||
| Q2 25 | $18.7M | $38.4M | ||
| Q1 25 | $50.9M | $24.3M | ||
| Q4 24 | $38.1M | $36.7M | ||
| Q3 24 | $33.4M | $30.2M | ||
| Q2 24 | $25.1M | $31.7M | ||
| Q1 24 | $41.5M | $30.8M |
| Q4 25 | — | $8.2M | ||
| Q3 25 | — | $8.6M | ||
| Q2 25 | $-154.0K | $14.7M | ||
| Q1 25 | $23.5M | $10.3M | ||
| Q4 24 | $18.9M | $14.5M | ||
| Q3 24 | $5.7M | $15.8M | ||
| Q2 24 | $-6.5M | $16.2M | ||
| Q1 24 | $13.8M | $15.1M |
| Q4 25 | — | 26.4% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 32.4% | ||
| Q1 25 | — | 29.2% | ||
| Q4 24 | — | 27.3% | ||
| Q3 24 | — | 29.2% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 33.6% |
| Q4 25 | — | 40.4% | ||
| Q3 25 | — | 33.7% | ||
| Q2 25 | -6.9% | 43.8% | ||
| Q1 25 | 44.4% | 47.7% | ||
| Q4 24 | 46.4% | 42.3% | ||
| Q3 24 | 12.3% | 50.8% | ||
| Q2 24 | -33.7% | 50.6% | ||
| Q1 24 | 28.1% | 54.3% |
| Q4 25 | — | 32.2% | ||
| Q3 25 | — | 30.0% | ||
| Q2 25 | -0.8% | 38.3% | ||
| Q1 25 | 46.2% | 42.3% | ||
| Q4 24 | 49.6% | 39.5% | ||
| Q3 24 | 17.2% | 52.4% | ||
| Q2 24 | -26.0% | 51.1% | ||
| Q1 24 | 33.3% | 49.1% |
| Q4 25 | — | $0.38 | ||
| Q3 25 | — | $0.35 | ||
| Q2 25 | — | $0.60 | ||
| Q1 25 | — | $0.41 | ||
| Q4 24 | — | $0.59 | ||
| Q3 24 | — | $0.64 | ||
| Q2 24 | — | $0.65 | ||
| Q1 24 | — | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $528.6M |
| Total Assets | $175.1M | $580.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.5M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $49.0M | $2.6M | ||
| Q1 25 | $47.6M | $3.4M | ||
| Q4 24 | $38.1M | $1.1M | ||
| Q3 24 | $40.6M | $570.0K | ||
| Q2 24 | $43.2M | $60.0K | ||
| Q1 24 | $36.2M | $621.0K |
| Q4 25 | — | $528.6M | ||
| Q3 25 | — | $521.6M | ||
| Q2 25 | $119.9M | $512.8M | ||
| Q1 25 | $25.0M | $503.7M | ||
| Q4 24 | $-456.0K | $494.0M | ||
| Q3 24 | $-23.5M | $479.3M | ||
| Q2 24 | $-31.2M | $463.2M | ||
| Q1 24 | $-31.7M | $450.4M |
| Q4 25 | — | $580.3M | ||
| Q3 25 | — | $557.9M | ||
| Q2 25 | $175.1M | $552.0M | ||
| Q1 25 | $98.5M | $544.6M | ||
| Q4 24 | $120.5M | $534.2M | ||
| Q3 24 | $139.0M | $521.4M | ||
| Q2 24 | $159.2M | $514.9M | ||
| Q1 24 | $184.7M | $510.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $19.0M |
| Free Cash FlowOCF − Capex | $-15.8M | $15.7M |
| FCF MarginFCF / Revenue | -84.6% | 61.6% |
| Capex IntensityCapex / Revenue | 0.1% | 13.1% |
| Cash ConversionOCF / Net Profit | — | 2.32× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $28.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $19.0M | ||
| Q3 25 | — | $7.2M | ||
| Q2 25 | $-15.8M | $6.1M | ||
| Q1 25 | $-21.0M | $4.9M | ||
| Q4 24 | $-19.9M | $7.9M | ||
| Q3 24 | $-20.7M | $13.8M | ||
| Q2 24 | $-19.5M | $3.5M | ||
| Q1 24 | $-26.0M | $10.8M |
| Q4 25 | — | $15.7M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | $-15.8M | $3.7M | ||
| Q1 25 | $-21.2M | $3.6M | ||
| Q4 24 | $-20.0M | $6.0M | ||
| Q3 24 | $-20.7M | $9.1M | ||
| Q2 24 | $-19.6M | $1.7M | ||
| Q1 24 | $-26.2M | $9.9M |
| Q4 25 | — | 61.6% | ||
| Q3 25 | — | 17.8% | ||
| Q2 25 | -84.6% | 9.6% | ||
| Q1 25 | -41.6% | 15.0% | ||
| Q4 24 | -52.5% | 16.4% | ||
| Q3 24 | -62.1% | 30.2% | ||
| Q2 24 | -78.2% | 5.4% | ||
| Q1 24 | -63.1% | 32.2% |
| Q4 25 | — | 13.1% | ||
| Q3 25 | — | 7.1% | ||
| Q2 25 | 0.1% | 6.2% | ||
| Q1 25 | 0.2% | 5.2% | ||
| Q4 24 | 0.2% | 5.1% | ||
| Q3 24 | 0.1% | 15.6% | ||
| Q2 24 | 0.4% | 5.5% | ||
| Q1 24 | 0.3% | 2.8% |
| Q4 25 | — | 2.32× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | -0.89× | 0.48× | ||
| Q4 24 | -1.05× | 0.54× | ||
| Q3 24 | -3.61× | 0.88× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | -1.89× | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LEGH
| Commercial Sales | $8.6M | 34% |
| Retail Store Sales | $6.0M | 24% |
| Inventory Finance Sales | $5.0M | 20% |
| Direct Sales | $4.4M | 17% |
| Other | $1.5M | 6% |
